Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. [electronic resource]
Producer: 20210305Description: 442-447 p. digitalISSN:- 1941-837X
- Antineoplastic Agents, Immunological -- adverse effects
- Cost-Benefit Analysis
- Head and Neck Neoplasms -- drug therapy
- Humans
- Models, Economic
- Neoplasm Recurrence, Local
- Nivolumab -- adverse effects
- Quality-Adjusted Life Years
- Squamous Cell Carcinoma of Head and Neck -- drug therapy
- Survival Analysis
- United States
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.